Maintaining fluoroquinolone class efficacy: Review of influencing factors

Emerging Infectious Diseases

Volumn 9, Issue 1, 2003, Pages 1-9

  Scheld, W Michael ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; METICILLIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRESCRIPTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 0037240273     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0901.020277     Document Type: Review

References (74)

1. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9:1065-78.
2. Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998;104:24S-33.
3. U.S. Congress, Office of Technology Assessment. Impacts of antibioticresistant bacteria. OTA-H-629. Washington: U.S. Government Printing Office; 1995.
4. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC Jr, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.
5. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
6. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
7. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-24.
8. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:1040-8.
9. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000;30:243-54.
10. Munshi MH, Sack DA, Haider K, Ahmed ZU, Rahaman MM, Morshed MG. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987;2:419-21.
11. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797-9.
12. Phillips I, King A, Shannon K. Comparative in-vitro properties of the quinolones. In: Andriole VT, editor. The quinolones. 3rd ed. San Diego: Academic Press; 2000. p. 99-137.
13. Blondeau JM. A review of the comparative in-vitro activities of 12 anti-microbial agents, with a focus on five new 'respiratory quinolones.' J Antimicrob Chemother 1999;43(Suppl B):S1-11.
14. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997;40:639-51.
15. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44:3351-6.
16. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones. Drugs 2002;62:13-59.
17. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl. 2):S81-93.
18. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative anti-anaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589-92.
19. Takahata M, Shimakura M, Hori R, Kizawa K, Todo Y, Minami S, et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001;45:312-5.
20. Richardson DC, Bast D, McGeer A, Low DE. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:1911-4.
21. Huang MB, Baker CN, Banerjee S, Tenover FC. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni and gram-negative bacteria resistant to anti-microbial agents. J Clin Microbiol 1992;30:3243-8.
22. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000;44:3049-54.
23. Weigel LM, Anderson GJ, Facklam RR, Tenover FC. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumonia. Antimicrob Agents Chemother 2001;45:3517-23.
24. Fuchs PC, Barry AL, Brown SD. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. Antimicrob Agents Chemother 1996;40:1633-9.
25. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JCS, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
26. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
27. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82.
28. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
29. Sahm DF, Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, Thornsberry C, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2 year longitudinal analysis. Antimicrob Agents Chemother 2001;45:1037-42.
30. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin Infect Dis 2000;31(Suppl 2):S16-23.
31. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002;34(Suppl 1):S4-16.
32. Peterson LR. Quinolone molecular structure-activity relationships: what have we learned about improving antibacterial activity. Clin Infect Dis 2001, 33(Suppl 3):S180-6.
33. Pestova E, Beyer R, Cianciotto NP, Noskin GA, Peterson LR. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae for resistance to novel fluoroquinolones. Antimicrob Agents Chemother 1999;43:2000-4.
34. Lu T, Zhao X, Drlica K. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8 methoxy group. Antimicrob Agents Chemother 1999;43:2969-74.
35. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000;45:583-90.
36. M'Zali FH, Hawkey PM, Thomson CJ. The comparative in vitro activity of ciprofloxacin and levofloxacin against clinical strains of Pseudomonas aeruginosa. Clin Microbiol Infect 2000;6(Suppl 1):91. Abstract WeP122.
37. Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin and trovafloxacin. Antimicrob Agents Chemother 2001;45:883-92.
38. Dalhoff A, Schubert S, Ullman U. Dissociated resistance among fluoroquinolones. J Antimicrob Chemother 2001;47(Suppl 1):33. abstract P67.
39. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-dynamic characteristics. Pharmacotherapy 2000;20:245-6.
40. Craig WA. Does the dose matter? Clin Infect Dis 2001;33(Suppl 3):S233-7.
41. Ciprofloxacin (Cipro) package insert. West Haven (CT): Bayer Corporation; 2001.
42. Levofloxacin (Levaquin) package insert. Rarotam (NJ): Ortho-McNeil Pharmaceuticals; 2001.
43. Moxifloxacin (Avelox) package insert. West Haven (CT): Bayer Corporation; 2001.
44. Gatifloxacin (Tequin) package insert. Princeton (NJ): Bristol-Myers-Squibb Pharmaceuticals, Princeton; 2001.
45. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.
46. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;33(Suppl 3):S147-56.
47. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433-8.
48. Hansen G, Blondeau JM, Drlica K, Zhao X. Evaluation of ciprofloxacin (C) and levofloxacin (L) by mutation prevention concentration (MPC) against 119 isolates of Pseudomonas aeruginosa (PA). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Dec 16-19, 2001. Washington: American Society for Microbiology; 2001. Abstract E-729.
49. Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA. Management of fluoroquinolone resistance in Pseudomonas aeruginosa - outcome of monitored use in a referral hospital. Int J Antimicrob Agents 1998;10:207-14.
50. Rifenburg RP, Paladino JA, Bhavnani SM, Den Haese D, Schentag JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm 1999;56:2217-23.
51. Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino JA, et al. An evaluation of fluoroquinolone expenditures and ciprofloxacin susceptibility of P. aeruginosa among U.S. hospitals. Pharmacotherapy 2001;21(Suppl):371a. Abstract 100.
52. Peterson L. Stability of antimicrobial activity against emerging resistance in Gram-negative pathogens recovered from hospitalized patients. In: Program and Abstracts from the 10th International Congress on Infectious Diseases, Hong Kong. March 11-14, 2002. Boston: International Congress of Infectious Diseases; 2002. Abstract 11.029.
53. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of drug consumption in human communities and the frequency of antibiotic resistance. Proc Natl Acad Sci U S A 1999;96:1152-6.
54. Zambrano CH, Postelnik MJ, Noskin GA. Relationship between antimicrobial usage and susceptibility in specific patient care areas: a 3-year assessment. Infectious Diseases Society of America 39th Annual Meeting, San Francisco, CA, Oct 25-28, 2001. Alexandria (VA): Infectious Diseases Society of American; 2001. Abstract 496.
55. Iannini PB, Tillotson GS. Impact of quinolone substitution on Pseudomonas aeruginosa resistance, antimicrobial usage and hospital costs: presented at the Antimicrobial Chemotherapy and Clinical Practice meeting, Genova, Italy, Oct 21-24, 2001. Pharmacotherapy 2001;21(Suppl):371. Abstract 111.
56. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Archibald LK, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999;29:245-52.
57. Hill HA, Haber MJ, McGowan JE, Fridkin SK, Edwards JR, Tenover FC, et al. A link between quinolone use and resistance in P. aeruginosa?: preliminary data from Project ICARE. Infectious Diseases Society of America 39th Annual Meeting, San Francisco, CA, Oct 25-28, 2001. Alexandria (VA): Infectious Diseases Society of America; 2001. Abstract 495.
58. Ho PL, Que TL, Tsang DN, Ng T-K, Chow K-H, Seto W-H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-3.
59. Ho PL, Yung RWH, Tsang DN, Que TL, Ho M, Seto WH, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001;48:659-65.
60. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
61. Ball AP, Tillotson GS. Lower respiratory tract infection therapy - the role of ciprofloxacin. J Int Med Res 1995;23:315-27.
62. Wortmann GW, Bennett SP. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin Infect Dis 1999;29:1599-600.
63. Fishman NO, Suh B, Weigel LM, Lorber B, Gelone S, Truant AL, et al. Three levofloxacin treatment failures of pneumococcal respiratory tract infections. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept 26-29, 1999. Washington: American Society for Microbiology; 1999. Abstract 825.
64. Kuehnert MJ, Nolte FS, Perlino CA. Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med 1999;131:312-3.
65. Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-8.
66. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001;35:687-90.
67. Piper J, Couch K, Tuttle D, Steele-Moore L. Epidemiology and clinical outcomes of patients with levofloxacin resistant pneumococcus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Dec 16-19, 2001. Washington: American Society for Microbiology; 2001. Abstract L-902.
68. Kays MB, Smith DW, Wack MF, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002;22:395-9.
69. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumoccal pneumoia. N Engl J Med;347:65-6.
70. Davies BI, Maesen FPV. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother 1999;43(Suppl C):83-90.
71. Sullivan JG, McElroy AD, Honsinger RW, McAdoo M, Harrison BJ, Plouffe JF, et al. Treating community-acquired pneumonia with once daily gatifloxacin vs once-daily levofloxacin. Journal of Respiratory Diseases 1999;20(Suppl):S49-59.
72. Weiss K, Restieri C, Gauthier R, Laverdiere M, McGeer A, Davidson R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-22.
73. Ho PL, Tse WS, Tsang KWT, Kwok TK, Ng TK, Cheng VCC, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-7.
74. Thomson KS. Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? J Antimicrob Chemother 2000;45:719-23.